MA54619A - Cristal de composé d'acide pyrophosphorique - Google Patents
Cristal de composé d'acide pyrophosphoriqueInfo
- Publication number
- MA54619A MA54619A MA054619A MA54619A MA54619A MA 54619 A MA54619 A MA 54619A MA 054619 A MA054619 A MA 054619A MA 54619 A MA54619 A MA 54619A MA 54619 A MA54619 A MA 54619A
- Authority
- MA
- Morocco
- Prior art keywords
- acid compound
- pyrophosphoric acid
- compound crystal
- crystal
- pyrophosphoric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018247437 | 2018-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54619A true MA54619A (fr) | 2021-11-03 |
Family
ID=71127176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054619A MA54619A (fr) | 2018-12-28 | 2019-12-27 | Cristal de composé d'acide pyrophosphorique |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12077524B2 (enExample) |
| EP (4) | EP3903785B1 (enExample) |
| JP (3) | JP6977185B2 (enExample) |
| CN (3) | CN120081826A (enExample) |
| ES (1) | ES2991904T3 (enExample) |
| MA (1) | MA54619A (enExample) |
| TW (3) | TWI834791B (enExample) |
| WO (1) | WO2020138481A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR122595A1 (es) | 2020-06-10 | 2022-09-21 | Mitsubishi Tanabe Pharma Corp | Agente profiláctico o terapéutico para fotodermatosis |
| KR102952931B1 (ko) | 2020-06-10 | 2026-04-15 | 다나베 파마 가부시키가이샤 | 포르피린증의 예방 또는 치료제 |
| CN122557552A (zh) * | 2020-06-10 | 2026-08-14 | 田边制药株式会社 | 卟啉症的预防或治疗剂 |
| CN117255786A (zh) * | 2021-05-06 | 2023-12-19 | 株式会社Lg 化学 | 黑皮质素受体激动剂化合物的晶型vii及其制备方法 |
| KR102854595B1 (ko) * | 2021-05-06 | 2025-09-03 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 결정형 v 및 이의 제조방법 |
| KR102854598B1 (ko) * | 2021-05-07 | 2025-09-03 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 황산염의 결정형 및 이의 제조방법 |
| JP2024517271A (ja) * | 2021-05-07 | 2024-04-19 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の有機酸塩の結晶形ｉｖおよびその製造方法 |
| US20240239769A1 (en) * | 2021-05-07 | 2024-07-18 | Lg Chem, Ltd. | Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same |
| KR20240145490A (ko) | 2022-01-31 | 2024-10-07 | 미쓰비시 타나베 파마 코퍼레이션 | 멜라노코르틴 1 수용체 아고니스트의 신규 용도 |
| WO2024029599A1 (ja) | 2022-08-03 | 2024-02-08 | 田辺三菱製薬株式会社 | １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005283326B2 (en) | 2004-09-13 | 2011-07-21 | Ono Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| EP1951286A4 (en) * | 2005-10-07 | 2009-11-04 | Waratah Pharmaceuticals Inc | COMBINED USE OF INHIBITORS OF DPP-IV AND GASTRIN COMPOUNDS |
| PT3150578T (pt) * | 2014-05-29 | 2021-01-18 | Mitsubishi Tanabe Pharma Corp | Novo composto de pirrolidina e aplicação como agonista do recetor de melanocortina |
| JP6392297B2 (ja) * | 2015-11-27 | 2018-09-19 | 田辺三菱製薬株式会社 | 医薬組成物 |
-
2019
- 2019-12-27 CN CN202510224370.1A patent/CN120081826A/zh active Pending
- 2019-12-27 MA MA054619A patent/MA54619A/fr unknown
- 2019-12-27 TW TW108148109A patent/TWI834791B/zh active
- 2019-12-27 EP EP19905349.7A patent/EP3903785B1/en active Active
- 2019-12-27 CN CN201980086473.9A patent/CN113226314B/zh active Active
- 2019-12-27 WO PCT/JP2019/051570 patent/WO2020138481A1/ja not_active Ceased
- 2019-12-27 ES ES19905349T patent/ES2991904T3/es active Active
- 2019-12-27 CN CN202510225181.6A patent/CN120081827A/zh active Pending
- 2019-12-27 TW TW113104509A patent/TWI870228B/zh active
- 2019-12-27 EP EP26175127.5A patent/EP4763282A2/en active Pending
- 2019-12-27 JP JP2020562542A patent/JP6977185B2/ja active Active
- 2019-12-27 US US17/418,563 patent/US12077524B2/en active Active
- 2019-12-27 EP EP25183270.5A patent/EP4603143A3/en active Pending
- 2019-12-27 TW TW113147267A patent/TWI919623B/zh active
- 2019-12-27 EP EP24193769.7A patent/EP4434582A3/en not_active Withdrawn
-
2021
- 2021-11-10 JP JP2021183553A patent/JP7652682B2/ja active Active
-
2024
- 2024-07-23 US US18/781,544 patent/US20250002474A1/en active Pending
-
2025
- 2025-03-14 JP JP2025041552A patent/JP2025085744A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2991904T3 (es) | 2024-12-05 |
| TWI919623B (zh) | 2026-03-21 |
| CN120081827A (zh) | 2025-06-03 |
| JP2025085744A (ja) | 2025-06-05 |
| WO2020138481A1 (ja) | 2020-07-02 |
| JP7652682B2 (ja) | 2025-03-27 |
| EP3903785A4 (en) | 2022-08-10 |
| EP4603143A3 (en) | 2025-11-05 |
| EP4603143A2 (en) | 2025-08-20 |
| EP3903785A1 (en) | 2021-11-03 |
| TWI870228B (zh) | 2025-01-11 |
| TW202039464A (zh) | 2020-11-01 |
| CN113226314A (zh) | 2021-08-06 |
| TW202421621A (zh) | 2024-06-01 |
| JPWO2020138481A1 (ja) | 2021-09-27 |
| CN120081826A (zh) | 2025-06-03 |
| EP3903785B1 (en) | 2024-10-02 |
| EP4434582A3 (en) | 2024-12-18 |
| US12077524B2 (en) | 2024-09-03 |
| TW202517631A (zh) | 2025-05-01 |
| JP2022024034A (ja) | 2022-02-08 |
| TWI834791B (zh) | 2024-03-11 |
| EP4434582A2 (en) | 2024-09-25 |
| JP6977185B2 (ja) | 2021-12-08 |
| US20250002474A1 (en) | 2025-01-02 |
| CN113226314B (zh) | 2025-03-18 |
| EP4763282A2 (en) | 2026-06-24 |
| US20220073497A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3903785A4 (en) | CRYSTAL OF A PYROPHOSPHORIC ACID COMPOUND | |
| EP4083038A4 (en) | PYRIDAZINYL THIAZOLECARBOXAMIDE COMPOUND | |
| PL3838888T3 (pl) | Triestry kwasu cykloheksanotripropionowego | |
| EP3473626A4 (en) | PYRROLOPYRIMIDINE CRYSTAL FOR PRODUCING JAK INHIBITORS | |
| MA42615A (fr) | Composés phosphodiamide antiviraux d'ester d'acide bêta-aminé | |
| EP3808783A4 (en) | Novel crosslinked alginic acid | |
| MA52877A (fr) | Acide hyaluronique stabilisé | |
| EP3766972A4 (en) | NUCLEIC ACID COMPLEX | |
| EP3612152A4 (en) | TOPICAL ADMINISTRATION OF NUCLEIC ACID COMPOUNDS | |
| FIC20260011I1 (fi) | nirogasestaatin dihydrobromidisuolan kiteinen muoto | |
| EP3930877C0 (en) | PRODUCTION OF CONCENTRATED USED DIALYSATE | |
| DK3823952T3 (da) | Oprensning af levulinsyre | |
| EP3808747A4 (en) | IMIDAZOPYRIDINONE COMPOUND | |
| EP4003323A4 (en) | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | |
| PL3976591T3 (pl) | Sposoby wytwarzania kwasu 5-bromo-2-(3-chloropirydyn-2-ylo)-2h- pirazolo-3-karboksylowego | |
| JOP20200030A1 (ar) | مركب خماسي الحلقة | |
| HUE063674T2 (hu) | Eljárás N-(amino-imino-metil)-2-aminoetánsav (III) metastabil kristálymódosulatának elõállítására | |
| EP3670630C0 (en) | NEW ALKYLSULFONIC ACID COMPOSITIONS | |
| DK3777858T3 (da) | Middel til at hæmme stigning af intraneuronal calciumkoncentration | |
| DK3278112T3 (da) | Sammensætning, der omfatter prostacyclin eller analoger deraf, til behandling af akut, kritisk syge patienter | |
| IL280441A (en) | Sulfopropanoic acid derivatives for treating neurodegenerative disorders | |
| MA49704A (fr) | Dérivés d'acide biliaire à marquage isotopique | |
| PT3845524T (pt) | Compostos de ácido benzoico e método de preparação destes e suas aplicações | |
| PL3665124T3 (pl) | Sposób kwasowego roztwarzania źródła fosforanowego | |
| DK3599243T3 (da) | 17beta-heterocyklyl-digitalis-lignende forbindelser til behandlingen af hjertesvigt |